Traders Buy Large Volume of Call Options on Moderna (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNAGet Free Report) was the recipient of some unusual options trading on Tuesday. Stock traders acquired 103,958 call options on the company. This is an increase of approximately 42% compared to the average daily volume of 73,225 call options.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. TD Cowen cut their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Argus cut Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler restated an “overweight” rating and issued a $69.00 target price (down previously from $115.00) on shares of Moderna in a research note on Monday, November 18th. Finally, The Goldman Sachs Group reduced their price target on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Moderna presently has a consensus rating of “Hold” and an average price target of $79.50.

Get Our Latest Research Report on Moderna

Moderna Stock Performance

Moderna stock traded up $5.37 during midday trading on Tuesday, reaching $47.94. 7,861,538 shares of the company traded hands, compared to its average volume of 6,477,841. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a 12 month low of $35.80 and a 12 month high of $170.47. The firm has a market capitalization of $18.45 billion, a price-to-earnings ratio of -8.24 and a beta of 1.60. The business has a 50 day moving average of $43.38 and a two-hundred day moving average of $71.48.

Moderna (NASDAQ:MRNAGet Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the business posted ($1.39) EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, research analysts predict that Moderna will post -9.3 earnings per share for the current year.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Moderna

Institutional investors have recently made changes to their positions in the business. Ashton Thomas Private Wealth LLC bought a new position in Moderna in the second quarter worth approximately $26,000. Plato Investment Management Ltd raised its holdings in Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after purchasing an additional 288 shares during the period. Blue Trust Inc. lifted its position in Moderna by 365.6% during the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares in the last quarter. Larson Financial Group LLC increased its position in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. raised its stake in shares of Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after buying an additional 778 shares during the period. Institutional investors own 75.33% of the company’s stock.

About Moderna

(Get Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.